Swedbank AB Increases Stake in Pfizer Inc. $PFE

Key Points

• Swedbank AB increased its stake in Pfizer by 3.7%, purchasing an additional 164,428 shares and now owning approximately 4.59 million shares valued at around $111 million.
• Pfizer reported earnings of $0.78 per share for the last quarter, exceeding analysts' expectations with revenue of $14.65 billion, a 10.3% increase year-over-year.
• The company declared a quarterly dividend of $0.43, resulting in an annualized dividend yield of 7.1%, with a payout ratio of 91.49%.

Swedbank AB raised its stake in shares of Pfizer Inc. (NYSE:PFE - Free Report) by 3.7% during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 4,586,829 shares of the biopharmaceutical company's stock after purchasing an additional 164,428 shares during the period. Swedbank AB owned 0.08% of Pfizer worth $111,185,000 as of its most recent SEC filing.

A number of other large investors have also recently bought and sold shares of the company. Gould Capital LLC raised its position in shares of Pfizer by 97.2% during the fourth quarter. Gould Capital LLC now owns 1,000 shares of the biopharmaceutical company's stock worth $27,000 after acquiring an additional 493 shares during the last quarter. GKV Capital Management Co. Inc. bought a new position in Pfizer during the 1st quarter valued at approximately $27,000. North Capital Inc. purchased a new position in Pfizer during the first quarter valued at $28,000. Bayforest Capital Ltd purchased a new stake in Pfizer during the first quarter valued at approximately $28,000. Finally, Bernard Wealth Management Corp. bought a new position in Pfizer in the fourth quarter worth approximately $30,000. Institutional investors and hedge funds own 68.36% of the company's stock.

Analyst Upgrades and Downgrades

A number of analysts have issued reports on PFE shares. Wall Street Zen raised Pfizer from a "hold" rating to a "buy" rating in a research report on Saturday. Morgan Stanley raised their target price on shares of Pfizer from $32.00 to $33.00 and gave the company an "equal weight" rating in a research note on Wednesday, August 6th. Berenberg Bank decreased their target price on shares of Pfizer from $28.00 to $25.00 and set a "hold" rating for the company in a research report on Thursday, May 29th. Citigroup increased their target price on shares of Pfizer from $25.00 to $26.00 and gave the stock a "neutral" rating in a research report on Wednesday, August 6th. Finally, Bank of America raised their price target on shares of Pfizer from $27.00 to $28.00 and gave the stock a "neutral" rating in a research report on Wednesday, August 6th. Two analysts have rated the stock with a Strong Buy rating, four have assigned a Buy rating, eleven have issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of "Hold" and a consensus target price of $28.12.

Pfizer Stock Down 0.5%

Shares of NYSE:PFE traded down $0.12 on Friday, hitting $24.03. 86,201,583 shares of the company's stock were exchanged, compared to its average volume of 39,901,288. The company has a market capitalization of $136.62 billion, a PE ratio of 12.78, a P/E/G ratio of 0.85 and a beta of 0.55. The firm's 50-day moving average is $24.63 and its 200 day moving average is $24.21. Pfizer Inc. has a 1-year low of $20.92 and a 1-year high of $30.43. The company has a debt-to-equity ratio of 0.65, a quick ratio of 0.85 and a current ratio of 1.16.

Pfizer (NYSE:PFE - Get Free Report) last posted its quarterly earnings data on Tuesday, August 5th. The biopharmaceutical company reported $0.78 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.58 by $0.20. Pfizer had a return on equity of 21.42% and a net margin of 16.84%.The business had revenue of $14.65 billion for the quarter, compared to analysts' expectations of $13.43 billion. During the same quarter last year, the firm earned $0.60 earnings per share. The business's revenue was up 10.3% on a year-over-year basis. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. Sell-side analysts predict that Pfizer Inc. will post 2.95 EPS for the current year.

Pfizer Dividend Announcement

The company also recently declared a quarterly dividend, which was paid on Tuesday, September 2nd. Stockholders of record on Friday, July 25th were issued a dividend of $0.43 per share. This represents a $1.72 dividend on an annualized basis and a dividend yield of 7.2%. The ex-dividend date of this dividend was Friday, July 25th. Pfizer's dividend payout ratio is 91.49%.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.